Основная статистика
| CIK | 1741830 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Kronos Bio, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. 001-39592 Commission File Number KRONOS BIO, INC. (Exact name of registrant as specified in its char |
|
| June 20, 2025 |
As filed with the Securities and Exchange Commission on June 20, 2025 As filed with the Securities and Exchange Commission on June 20, 2025 Registration No. |
|
| June 20, 2025 |
As filed with the Securities and Exchange Commission on June 20, 2025 As filed with the Securities and Exchange Commission on June 20, 2025 Registration No. |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date earliest event reported): June 20, 2025 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 20, 2025 |
As filed with the Securities and Exchange Commission on June 20, 2025 As filed with the Securities and Exchange Commission on June 20, 2025 Registration No. |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) KRONOS BIO, INC. (Name of Subject Company (Issuer)) CONCENTRA MERGER SUB IV, INC. (Name of Filing Persons (Co-Offeror 1)) CONCENTRA BIOSCIENCES, LLC (Name of Filing Persons (Parent of Offeror)) TANG CA |
|
| June 20, 2025 |
AMENDED AND RESTATED BYLAWS KRONOS BIO, INC. (a Delaware corporation) Article I CORPORATE OFFICES Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF KRONOS BIO, INC. (a Delaware corporation) Article I CORPORATE OFFICES Section 1.1 Registered Office. The registered office of Kronos Bio, Inc. (the “Corporation”) shall be fixed in the Certificate of Incorporation of the Corporation (as may be amended or modified from time to time, the “Certificate of Incorporation”). Section 1.2 Other Offices. The Corpor |
|
| June 20, 2025 |
As filed with the Securities and Exchange Commission on June 20, 2025 As filed with the Securities and Exchange Commission on June 20, 2025 Registration No. |
|
| June 20, 2025 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Kronos Bio, INC. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF Kronos Bio, INC. I. The name of this corporation is Kronos Bio, Inc. (the “Corporation”). II. The registered office of the Corporation in the State of Delaware shall be Corporation Service Center, 251 Little Falls Drive, Wilmington, New Castle County, Delaware, 19808, and the name of the registered agent of the Corporation in the Sta |
|
| June 20, 2025 |
As filed with the Securities and Exchange Commission on June 20, 2025 As filed with the Securities and Exchange Commission on June 20, 2025 Registration No. |
|
| June 20, 2025 |
CONTINGENT VALUE RIGHTS AGREEMENT Exhibit (d)(6) CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of June 20, 2025 (this “Agreement”), is entered into by and between Concentra Biosciences, LLC, a Delaware limited liability company (the “Parent”), Concentra Merger Sub IV, Inc. |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) Kronos Bio, Inc. (Name of Subject Company) Kronos Bio, Inc. (Name of Persons Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 50107A104 (CUSIP Number of C |
|
| June 20, 2025 |
As filed with the Securities and Exchange Commission on June 20, 2025 As filed with the Securities and Exchange Commission on June 20, 2025 Registration No. |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date earliest event reported): June 4, 2025 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 5, 2025 |
TABLE OF CONTENTS Exhibit (a)(1)(A) Amended and Restated Offer to Purchase All Outstanding Shares of Common Stock of KRONOS BIO, INC. |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) KRONOS BIO, INC. (Name of Subject Company (Issuer)) CONCENTRA MERGER SUB IV, INC. (Name of Filing Persons (Co-Offeror 1)) CONCENTRA BIOSCIENCES, LLC (Name of Filing Persons (Parent of Offeror)) TANG CA |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) Kronos Bio, Inc. (Name of Subject Company) Kronos Bio, Inc. (Name of Persons Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 50107A104 (CUSIP Number of C |
|
| May 15, 2025 |
Exhibit 107 Calculation of Filing Fee Tables SC TO-T (Form Type) Kronos Bio, Inc. (Name of Subject Company – Issuer) Concentra Merger Sub IV, Inc. (Names of Filing Persons — Offeror) Concentra Biosciences, LLC (Names of Filing Persons — Parent of Offeror) Table 1: Transaction Valuation Transaction Valuation* Fee Rate Amount of Filing Fee** Fees to Be Paid $44,440,158.37 0.00015310 $6,803.79 Fees P |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Kronos Bio, Inc. (Name of Subject Company) Kronos Bio, Inc. (Name of Persons Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 50107A104 (CUSIP Number of Class of Securities |
|
| May 15, 2025 |
Exhibit (e)(3) TENDER AND SUPPORT AGREEMENT This SUPPORT AGREEMENT (“Agreement”), dated as of May 1, 2025, is made by and among Concentra Biosciences, LLC, a Delaware limited liability company (“Parent”), Concentra Merger Sub IV, Inc. |
|
| May 15, 2025 |
Exhibit (d)(2) CONFIDENTIALITY AGREEMENT This CONFIDENTIALITY AGREEMENT (this “Agreement”), is dated as of March 20, 2025, by and between the party disclosing information under this Agreement, Kronos Bio, Inc. |
|
| May 15, 2025 |
Exhibit (a)(1)(B) Letter of Transmittal To Tender Shares of Common Stock of KRONOS BIO, INC. |
|
| May 15, 2025 |
Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of KRONOS BIO, INC. |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 KRONOS BIO, INC. (Name of Subject Company (Issuer)) CONCENTRA MERGER SUB IV, INC. (Name of Filing Persons (Co-Offeror 1)) CONCENTRA BIOSCIENCES, LLC (Name of Filing Persons (Parent of Offeror)) TANG CAPITAL PARTNERS, LP |
|
| May 15, 2025 |
TABLE OF CONTENTS Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of KRONOS BIO, INC. |
|
| May 15, 2025 |
Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of KRONOS BIO, INC. |
|
| May 15, 2025 |
Exhibit (d)(3) Execution Version LIMITED GUARANTY This Limited Guaranty, dated as of May 1, 2025 (as may be amended, restated, supplemented or otherwise modified, this “Limited Guaranty”), by Tang Capital Partners, LP (the “Guarantor”), is made in favor of Kronos Bio, Inc. |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39592 Kronos Bi |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date earliest event reported): May 1, 2025 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Kronos Bio, Inc. (Name of Subject Company) Kronos Bio, Inc. (Name of Persons Filing Statement) COMMON STOCK, PAR VALUE $ 0.001 PER SHARE (Title of Class of Securities) 62857M105 (CUSIP Number of Class of Securitie |
|
| May 1, 2025 |
Exhibit 10.1 FORM OF CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [●] (this “Agreement”), is entered into by and between Concentra Biosciences, LLC, a Delaware limited liability company (the “Parent”), Concentra Merger Sub IV, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the “Purchaser”), [●], as Rights Agent (as defined herein), an |
|
| May 1, 2025 |
Exhibit 99.1 Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right CAMBRIDGE, Mass., May 1, 2025 – Kronos Bio, Inc. (“Kronos Bio”) (Nasdaq: KRON), a biotechnology company that has been developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, today announced that it |
|
| May 1, 2025 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER DATED AS OF May 1, 2025 AMONG CONCENTRA BIOSCIENCES, LLC, CONCENTRA MERGER SUB IV, INC. AND KRONOS BIO, INC. Table of Contents Page Article I DEFINITIONS 2 Section 1.01 Definitions 2 Section 1.02 Interpretation and Rules of Construction 12 Article II THE OFFER 13 Section 2.01 The Offer 13 Section 2.02 Company Actions 17 Article III THE MERGER 18 Section 3.0 |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001- |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2025 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 18, 2025 |
Execution Version CONFIDENTIAL SUBJECT TO [***] AGREEMENT Exhibit 10.13 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. TRANSITION AGREEMENT AND MUTUAL GENERAL RELEAS |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39592 Kronos Bio, In |
|
| March 18, 2025 |
Kronos Bio Reports Fourth-Quarter and Full-Year 2024 Financial Results Exhibit 99.1 Kronos Bio Reports Fourth-Quarter and Full-Year 2024 Financial Results SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 – Kronos Bio, Inc. (Nasdaq: KRON), a biopharmaceutical company, today reported fourth quarter and full year 2024 financial results Fourth Quarter and Full Year 2024 Financial Results ▪Cash, cash equivalents and investments: Cash, cash equivalents and investmen |
|
| March 18, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 18, 2025 |
Kronos Bio, Inc. Insider Trading Policy Exhibit 19.1 KRONOS BIO, INC. INSIDER TRADING POLICY Persons Covered This Insider Trading Policy of Kronos Bio, Inc. (the “Company”) applies to all directors, officers, other employees and consultants of the Company and any subsidiaries. It also applies to their family members who reside with them, anyone else who lives in their households and any family members who do not live in their households |
|
| December 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2024 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2024 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File |
|
| November 14, 2024 |
KRON / Kronos Bio, Inc. - 4.91% 2023-11-01 / Omega Fund V, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d815647dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2) Kronos Bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 50107A104 (CUSIP Number) September 30, |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39592 Krono |
|
| November 13, 2024 |
Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives – Discontinuing development of istisociclib, a CDK9 inhibitor; benefit-risk profile in platinum-resistant high-grade serous ovarian cancer does not support further development – – Kronos Bio Board of Directors has approved plan to evaluate strategic alternatives to maximize stockholder value – – Kronos Bio’s additional pipeline assets include preclinical p300 KAT inhibitor programs in oncology and autoimmune disease – — $124. |
|
| November 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File |
|
| November 12, 2024 |
KRONOS BIO, INC. 1300 So. El Camino Real, Suite 400 San Mateo, California 94402 November 12, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tim Buchmiller Re: Kronos Bio, Inc. Registration Statement on Form S-3 (File No. 333-283072) Request for Acceleration of Effective Date Ladies and Gentlemen: Kronos Bio, In |
|
| November 7, 2024 |
As filed with the Securities and Exchange Commission on November 7, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 7, 2024 Registration No. |
|
| November 7, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File |
|
| November 7, 2024 |
KRONOS BIO, INC., Dated as of [●], 20__ Debt Securities Table Of Contents Exhibit 4.6 KRONOS BIO, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20 Debt Securities Table Of Contents Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Section 2. |
|
| November 7, 2024 |
Calculation of Filing Fee Tables FORM S-3 Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) Kronos Bio, Inc. |
|
| November 7, 2024 |
Exhibit 4.10 Kronos Bio, Inc. and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of Kronos Bio, Inc. Form of Debt Securities Warrant Agreement This Debt Securities Warrant Agreement (this “Agreement”), dated as of [●], between Kronos Bio, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the law |
|
| November 7, 2024 |
Exhibit 4.9 Kronos Bio, Inc. and , As Warrant Agent Form of Preferred Stock Warrant Agreement Dated As Of Kronos Bio, Inc. Form of Preferred Stock Warrant Agreement This Preferred Stock Warrant Agreement (this “Agreement”), dated as of [●], between Kronos Bio, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws |
|
| November 7, 2024 |
Exhibit 4.8 Kronos Bio, Inc. and , As Warrant Agent Form of Common Stock Warrant Agreement Dated As Of Kronos Bio, Inc. Form of Common Stock Warrant Agreement This Common Stock Warrant Agreement (this “Agreement”), dated as of [●], between Kronos Bio, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] a |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39592 Kronos Bio |
|
| August 8, 2024 |
Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update — First patient in platinum-resistant high-grade serous ovarian cancer cohort was dosed on optimized dose and schedule with istisociclib (KB-0742); expect data update in 1H 2025 — — KB-9558 IND-enabling studies for multiple myeloma remain on track to be completed in Q4 2024 — — Pipeline update includes an additional indication for KB-9558 in HPV-driven tumors and a separate p300 program focused on autoimmune indications — — $136. |
|
| July 2, 2024 |
KRON / Kronos Bio, Inc. - 4.91% 2023-11-01 / BISCHOFBERGER NORBERT W - SC 13D/A Activist Investment SC 13D/A 1 ef20032081sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* KRONOS BIO, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 50107A104 (CUSIP Number) Norbert Bischofberger, Ph.D. 1300 So. El Camino Real, Suite 400 San Mateo, California 94402 Telephone: (650) 7 |
|
| June 27, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 12, 2024 |
KRON / Kronos Bio, Inc. - 4.91% 2023-11-01 / BISCHOFBERGER NORBERT W - SC 13D/A Activist Investment SC 13D/A 1 ef20031088formsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* KRONOS BIO, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 50107A104 (CUSIP Number) Norbert Bischofberger, Ph.D. 1300 So. El Camino Real, Suite 400 San Mateo, California 94402 Telephone: (65 |
|
| June 12, 2024 |
EX-99.A 2 ef20031088ex99-a.htm EXHIBIT A Exhibit A JOINT FILING STATEMENT I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the Common Stock of Kronos Bio, Inc. is filed on behalf of each of the undersigned. Dated: June 12, 2024 /s/ Norbert Bischofberger, Ph.D. Norbert Bischofberger, Ph.D. Norbert W. & Inger A. Bischofberger Rev |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 21, 2024 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (“Agreement”) is made and entered into by and between Kronos Bio, Inc. (the “Company”) and Deborah Knobelman (“Employee”) effective as of June 3, 2024 (the “Effective Date”). RECITALS WHEREAS, the Company desires to employ Employee on the terms and conditions set forth herein; and WHEREAS, Employee desires to be employ |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2024 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39592 Kronos Bi |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 9, 2024 |
Kronos Bio Reports First-Quarter 2024 Financial Results — $152.0 million cash runway into the second half of 2026 — — A study update on KB-0742-1001 will be presented at the upcoming American Society of Clinical Oncology (ASCO); expansion cohorts at new dose schedule remain on track to open in Q3 2024 — — KB-9558 remains on track with IND-enabling studies expected to complete in 2024 with first-in |
|
| April 29, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by R |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ |
|
| March 21, 2024 |
KRONOS BIO, INC. Incentive Compensation Recoupment Policy 1.Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Kronos Bio, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for |
|
| March 21, 2024 |
KRONOS BIO, INC. January 24, 2024 Jorge DiMartino, M.D., Ph.D. Re: Separation Agreement Dear Jorge: This letter sets forth the terms of the separation agreement (this “Agreement”) that Kronos Bio, Inc. (the “Company”) is offering to you to aid in your employment transition from the Company. 1.Separation Date. You agree and acknowledge that your Company employment will terminate on February 16, 202 |
|
| March 21, 2024 |
As filed with the Securities and Exchange Commission on March 21, 2024 As filed with the Securities and Exchange Commission on March 21, 2024 Registration No. |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39592 Kronos Bio, In |
|
| March 21, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 21, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Kronos Bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity 2020 Equity Incentive Plan Commo |
|
| March 21, 2024 |
Exhibit 99.1 Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half of 2025 IND-enabling studies for KB-9558 expected to complete in 2024 with first-in-hum |
|
| March 21, 2024 |
KRONOS BIO, INC. January 24, 2024 Barbara Kosacz Re: Separation Agreement Dear Barbara: This letter sets forth the terms of the separation agreement (this "Agreement") that Kronos Bio, Inc. (the "Company") is offering to you to aid in your employment transition from the Company. 1.Separation Date. You agree and acknowledge that your Company employment will terminate on February 16, 2024 (the "Sepa |
|
| March 7, 2024 |
Regulation FD Disclosure, Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2024 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File |
|
| November 27, 2023 |
KRON / Kronos Bio Inc - 4.91% 2023-11-01 / BISCHOFBERGER NORBERT W - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* KRONOS BIO, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 50107A104 (CUSIP Number) Norbert Bischofberger, Ph.D. 1300 So. El Camino Real, Suite 400 San Mateo, California 94402 Telephone: (650) 781-5200 (Name, Address and Telephone Numbe |
|
| November 13, 2023 |
Consulting Agreement by and between the Company and FLG Partners, LLC, dated September 8, 2023. Exhibit 10.1 CONFIDENTIAL CONSULTING AGREEMENT This Confidential Consulting Agreement (the “Agreement”) is executed as of the date shown on the signature page (the “Effective Date”), by and between FLG Partners, LLC, a California limited liability company (“FLG”), and the entity identified on the signature page (“Client”). RECITALS WHEREAS, FLG is in the business of providing certain financial ser |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39592 Krono |
|
| November 13, 2023 |
Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results Company presented positive preliminary data from Phase 1 dose escalation portion of Phase 1/2 KB-0742 study at the AACR-NCI-EORTC and CTOS conferences Optimization of resource allocation, restructuring and cost containment extends runway into 2026 Company on track to provide an update on KB-0742 escalation and expansion data as well as lanraplenib expansion cohort data in mid-2024 $198. |
|
| November 2, 2023 |
Regulation FD Disclosure, Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2023 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File |
|
| October 5, 2023 |
Identification of Original Research: Exhibit 99.1 Identification of Original Research: Original Research Identification of Clinical Trials: Clinical Trial, ClinicalTrials.gov Identifier: NCT04718675 Funding Source: Kronos Bio; Biotechnology Company. AACR/NCI/EORTC submission details: Submitted on behalf of authors by Crystal Kraft, MJH Life Sciences, [email protected] AACR/NCI/EORTC Member Sponsor: Presenting author: Corresp |
|
| October 5, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2023 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File N |
|
| September 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2023 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39592 Kronos Bio |
|
| August 8, 2023 |
Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial Results Data from the Phase 1 dose escalation portion of the Phase 1/2 KB-0742 study will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 2023 The Company recently opened the third dosing cohort in the escalation portion of the Phase 1b/2 study of lanraplenib in combination with gilteritinib FLT3-mutated relapsed/refractory acute myeloid leukemia $219. |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No.1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2023 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (C |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No.1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2023 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Co |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39592 Kronos Bi |
|
| May 10, 2023 |
Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial Results Enrollment ongoing in expansion portion of Phase 1/2 KB-0742 study, with initial efficacy data expected in 2H 2023 Phase 1b/2 study of lanraplenib in combination with gilteritinib in FLT3-mutated AML on track to report recommended Phase 2 dose and initial data in Q4 2023 or Q1 2024 Katherine Vega Stultz and Roger Dansey, M. |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| April 27, 2023 |
Table of Contents SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 27, 2023 |
Proxy Statement Pursuant to Section 14(a) of the SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2023 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2023 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No.1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2023 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) |
|
| March 15, 2023 |
As filed with the Securities and Exchange Commission on March 15, 2023 As filed with the Securities and Exchange Commission on March 15, 2023 Registration No. |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39592 Kronos Bio, In |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 15, 2023 |
Exhibit 99.1 Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2022 Financial Results First patient dosed in expansion portion of KB-0742 Phase 1/2 study, with initial efficacy results expected in 2H 2023 Recommended Phase 2 dose and initial data from Phase 1b/2 study of lanraplenib in combination with gilteritinib in FLT3-mutated AML on track to report in Q4 2023 or Q1 |
|
| March 15, 2023 |
Exhibit 4.4 DESCRIPTION OF COMMON STOCK The following summary description of the common stock of Kronos Bio, Inc. (we, our or us) is based on the provisions of our amended and restated certificate of incorporation, as well as our amended and restated bylaws, and the applicable provisions of the Delaware General Corporation Law. This information is qualified entirely by reference to the applicable |
|
| March 15, 2023 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT KRONOS BIO, INC. |
|
| March 15, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Kronos Bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity 2020 Equity Incentive Plan Commo |
|
| February 13, 2023 |
KRON / Kronos Bio Inc - 4.91% 2023-11-01 / Omega Fund V, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d459338dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1) Kronos Bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 50107A104 (CUSIP Number) December 31, |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Kronos Bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 50107A104 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| February 9, 2023 |
KRON / Kronos Bio Inc - 4.91% 2023-11-01 / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01262-kronosbioinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Kronos Bio Inc. Title of Class of Securities: Common Stock CUSIP Number: 50107A104 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the r |
|
| January 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2023 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39592 Krono |
|
| November 8, 2022 |
Kronos Bio Reports Recent Business Progress and Third-Quarter 2022 Financial Results Earlier today, company announced prioritization of clinical portfolio to focus on next-generation SYK inhibitor, lanraplenib and CDK9 inhibitor, KB-0742 $270. |
|
| November 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File |
|
| September 9, 2022 |
Exhibit 10.1 KRONOS BIO, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY ADOPTED: SEPTEMBER 30, 2020 AMENDED: FEBRUARY 16, 2022 Each member of the Board of Directors (the ?Board?) of Kronos Bio, Inc. (the ?Company?) who is a non-employee director of the Company (each such member, a ?Non-Employee Director?) will receive the compensation described in this Non-Employee Director Compensation Policy (th |
|
| September 9, 2022 |
Exhibit 10.3 Kronos Bio, Inc. Severance and Change in Control Plan Section 1. Introduction. The Kronos Bio, Inc. Severance and Change in Control Plan (the ?Plan?) is hereby established by the Board of Directors of Kronos Bio, Inc. (the ?Company?) effective upon the Effective Date (as defined below). The purpose of the Plan is to provide for the payment of severance and/or Change in Control (as def |
|
| September 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A (Amendment No. 1) (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: |
|
| September 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A (Amendment No. 1) (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: |
|
| September 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001- |
|
| August 4, 2022 |
Kronos Bio Reports Recent Business Progress and Second-Quarter 2022 Financial Results Company continuing to enroll patients in both Phase 3 registrational AGILITY trial of entospletinib and Phase 1/2 KB-0742 trial; both programs remain on track Preclinical data at EHA further support rationale to develop SYK inhibitors in genetically defined subsets of AML $292. |
|
| August 4, 2022 |
272536548 v2 1 ACTION BY UNANIMOUS WRITTEN CONSENT OF THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF KRONOS BIO, INC. |
|
| August 4, 2022 |
Non-Employee Director Compensation Policy, as amended KRONOS BIO, INC. SEVERANCE AND CHANGE IN CONTROL PLAN Section 1. INTRODUCTION. The Kronos Bio, Inc. Severance and Change in Control Plan (the ?Plan?) is hereby established by the Board of Directors of Kronos Bio, Inc. (the ?Company?) effective upon the Effective Date (as defined below). The purpose of the Plan is to provide for the payment of severance and/or Change in Control (as defined below) b |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39592 Kronos Bio |
|
| June 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2022 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39592 Kronos Bi |
|
| May 4, 2022 |
Kronos Bio Reports Recent Business Progress and First-Quarter 2022 Financial Results Preclinical data on CDK9 inhibitor KB-0742 presented at AACR add to evidence of potential activity in MYC-amplified and transcriptionally addicted tumors; company plans to announce RP2D and additional Phase 1 data in Q4 2022 $315. |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 27, 2022 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 27, 2022 |
DEF 14A 1 ny20003075x1def14a.htm DEF 14A SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Def |
|
| April 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2022 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 21, 2022 |
Kronos Bio, Inc. Severance and Change in Control Plan Section 1.Introduction. The Kronos Bio, Inc. Severance and Change in Control Plan (the ?Plan?) is hereby established by the Board of Directors of Kronos Bio, Inc. (the ?Company?) effective upon the Effective Date (as defined below). The purpose of the Plan is to provide for the payment of severance and/or Change in Control (as defined below) be |
|
| February 25, 2022 |
As filed with the Securities and Exchange Commission on February 25, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on February 25, 2022 Registration No. |
|
| February 24, 2022 |
Exhibit 99.1 Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2021 Financial Results Phase 1/2 trial of CDK9 inhibitor KB-0742 continues to enroll patients in the dose escalation stage, with announcement of recommended Phase 2 dose and Phase 1 data expected in Q4 2022 Lanraplenib trial to start in Q1 2022; Phase 3 registrational AGILITY trial of entospletinib underway, |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File |
|
| February 24, 2022 |
As filed with the Securities and Exchange Commission on February 24, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on February 24, 2022 Registration No. |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39592 Kronos Bio, In |
|
| February 24, 2022 |
Exhibit 10.13 May 28, 2020 Christopher Dinsmore, Ph.D. 24 Chester Street Newton, MA 02461 Re: Employment Letter Dear Dr. Dinsmore: Kronos Bio, Inc. (the ?Company?) is pleased to offer you the position of Chief Scientific Officer of the Company, on the following terms and conditions: 1.Title; Reporting; Duties. (a)As Chief Scientific Officer, you will perform such duties as are customarily provided |
|
| February 24, 2022 |
Description of Registrant’s Common Stock. Exhibit 4.4 DESCRIPTION OF COMMON STOCK The following summary description of the common stock of Kronos Bio, Inc. (we, our or us) is based on the provisions of our amended and restated certificate of incorporation, as well as our amended and restated bylaws, and the applicable provisions of the Delaware General Corporation Law. This information is qualified entirely by reference to the applicable |
|
| February 24, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Post-Effective Amendment to Form S-3 (Form Type) Kronos Bio, Inc. |
|
| February 24, 2022 |
As filed with the Securities and Exchange Commission on February 24, 2022 As filed with the Securities and Exchange Commission on February 24, 2022 Registration No. |
|
| February 24, 2022 |
EX-FILING FEES 4 ny20002924x3ex107.htm FILING FEES TABLE Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Kronos Bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of |
|
| February 17, 2022 |
KRON / Kronos Bio Inc - 4.91% 2023-11-01 / Belldegrun Arie - SC 13GA Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) KRONOS BIO, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 50107A104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| February 17, 2022 |
CUSIP No. 50107A104 13G Page 13 of 13 Pages Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendm |
|
| February 17, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the common sto |
|
| February 17, 2022 |
KRON / Kronos Bio Inc - 4.91% 2023-11-01 / BISCHOFBERGER NORBERT W - SC 13GA Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) KRONOS BIO, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 50107A104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Kronos Bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 50107A104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Kronos Bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 50107A104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| February 10, 2022 |
KRON / Kronos Bio Inc - 4.91% 2023-11-01 / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Kronos Bio Inc. Title of Class of Securities: Common Stock CUSIP Number: 50107A104 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13 |
|
| December 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2021 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File |
|
| November 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2021 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2021 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporati |
|
| November 12, 2021 |
8-K 1 kronos111121roshawnbluntbo.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisd |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39592 Krono |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File |
|
| November 9, 2021 |
Kronos Bio Reports Recent Business Progress and Third-Quarter Financial Results Company today announces progression of two discovery programs within its pipeline Highlights from the quarter include presentation of preclinical data on the company?s CDK9 inhibitor KB-0742 at AACR-NCI-EORTC meeting in October; Kronos Bio remains on track to report interim data from ongoing Phase 1/2 trial of KB-0742 by year end $398. |
|
| November 9, 2021 |
Form of Indenture, between the registrant and one or more trustees to be named. Exhibit 4.6 Kronos Bio, Inc., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Debt Securities Table Of Contents Page article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 Sectio |
|
| November 9, 2021 |
Open Market Sale Agreement, dated November 9, 2021, by and between the registrant and Jefferies LLC. Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM November 9, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Kronos Bio, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s common stock, |
|
| November 9, 2021 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.9 KRONOS BIO, INC. and , As Warrant Agent Form of Preferred Stock Warrant Agreement Dated As Of Exhibit 4.9 Kronos Bio, Inc. Form of Preferred Stock Warrant Agreement This Preferred Stock Warrant Agreement (this ?Agreement?), dated as of [?], between Kronos Bio, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing un |
|
| November 9, 2021 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.8 KRONOS BIO, INC. and , As Warrant Agent Form of Common Stock Warrant Agreement Dated As Of Exhibit 4.8 Kronos Bio, Inc. Form of Common Stock Warrant Agreement This Common Stock Warrant Agreement (this ?Agreement?), dated as of [?], between Kronos Bio, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing under the l |
|
| November 9, 2021 |
As filed with the Securities and Exchange Commission on November 9, 2021 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 9, 2021 Registration No. |
|
| November 9, 2021 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.10 Kronos Bio, Inc. and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of Exhibit 4.10 Kronos Bio, Inc. Form of Debt Securities Warrant Agreement This Debt Securities Warrant Agreement (this ?Agreement?), dated as of [?], between Kronos Bio, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing |
|
| August 12, 2021 |
Kronos Bio Reports Recent Business Progress and Second Quarter Financial Results Announced FDA clearance of Investigational New Drug application (IND) for lanraplenib (LANRA) for treatment of patients with acute myeloid leukemia (AML) Unveiled SYK portfolio strategy and highlighted momentum of CDK9 inhibitor and discovery programs at virtual R&D Day $419. |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39592 Kronos Bio |
|
| June 25, 2021 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2021 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) |
|
| June 24, 2021 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2021 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 25, 2021 |
EXHIBIT 99.1 Kronos Bio to Highlight Progress Across Pipeline and Outline Growth Strategy at Virtual R&D Day Today Unveils development strategy for lanraplenib (LANRA), which will expand addressable patient population for SYK inhibitor portfolio in acute myeloid leukemia (AML); plans to initiate two Phase 1/2 trials in late 2021 and early 2022 On track to initiate registrational Phase 3 trial for |
|
| May 25, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2021 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39592 Kronos Bi |
|
| May 11, 2021 |
Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces Virtual R&D Day Virtual R&D Day on May 25 to unveil SYK portfolio development strategy and highlight momentum of CDK9 inhibitor program and differentiated drug discovery platform Preclinical data for KB-0742 presented at the American Association for Cancer Research (AACR) Annual Meeting demonstrated sustained inhibition of tumor growth in multiple cancers $440. |
|
| May 11, 2021 |
Second Amendment to Office Lease, dated February 8, 2021, CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED, AND THE EXCLUDED TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH THREE ASTERISKS [***]. |
|
| May 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2021 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 4, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the common sto |
|
| May 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) KRONOS BIO, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 50107A104 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| April 27, 2021 |
SCHEDULE 14A INFORMATION ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 27, 2021 |
SCHEDULE 14A INFORMATION ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2021 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 23, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 kronos123120208kearnings.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2021 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdictio |
|
| March 23, 2021 |
As filed with the Securities and Exchange Commission on March 23, 2021 Registration No. |
|
| March 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39592 Kronos Bio, In |
|
| March 23, 2021 |
Exhibit 99.1 Kronos Bio Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results Positive End-of-Phase 2 meeting with the FDA for entospletinib in newly diagnosed NPM1-mutated acute myeloid leukemia First patient dosed in Phase 1/2 trial of KB-0742, an oral CDK9 inhibitor targeting MYC-amplified cancers $462.1 million in cash, cash equivalents and investments as of |
|
| March 23, 2021 |
Exhibit 10.13 May 28, 2020 Christopher Dinsmore, Ph.D. 24 Chester Street Newton, MA 02461 Re: Employment Letter Dear Dr. Dinsmore: Kronos Bio, Inc. (the ?Company?) is pleased to offer you the position of Chief Scientific Officer of the Company, on the following terms and conditions: 1.Title; Reporting; Duties. (a)As Chief Scientific Officer, you will perform such duties as are customarily provided |
|
| March 23, 2021 |
Exhibit 4.4 DESCRIPTION OF COMMON STOCK The following summary description of the common stock of Kronos Bio, Inc. (we, our or us) is based on the provisions of our amended and restated certificate of incorporation, as well as our amended and restated bylaws, and the applicable provisions of the Delaware General Corporation Law. This information is qualified entirely by reference to the applicable |
|
| March 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2021 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Kronos Bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 50107A104 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| February 12, 2021 |
EX-99.2 CUSIP NO. 50107A104 13 G Exhibit 99.2 POWER OF ATTORNEY Know all by these presents, that each of the undersigned hereby constitutes and appoints each other undersigned, such person’s true and lawful attorney-in-fact, to: (1) execute for and on behalf of each of such person Forms 3, 4, and 5 and Schedules 13D or 13G, as appropriate, and any required amendments thereto (collectively, the “Re |
|
| February 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 Kronos Bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 50107A104 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Stateme |
|
| February 12, 2021 |
EX-99.1 CUSIP NO. 50107A104 13 G Exhibit 99.1 AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Kronos Bio, Inc. Dated: February 12, 2021 OMEGA FUND V, L.P. BY: |
|
| February 10, 2021 |
Entry into a Material Definitive Agreement - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2021 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File |
|
| January 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2021 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File |
|
| December 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2020 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File |
|
| November 18, 2020 |
July 15, 2020 Barbara A. Kosacz 28140 Story Hill Lane Los Altos Hills, CA 94022 Re: Employment Letter Dear Ms. Kosacz: Kronos Bio, Inc. (the “Company”) is pleased to offer you the position of Chief Operating Officer and General Counsel of the Company, on the following terms and conditions (the “Agreement”): 1.Title; Reporting; Duties. (a)As Chief Operating Officer and General Counsel, you will per |
|
| November 18, 2020 |
Exhibit 99.1 Kronos Bio Reports Recent Business Progress and Third Quarter 2020 Financial Results Acquired from Gilead Sciences a portfolio of SYK inhibitors, including lead investigational therapy entospletinib being developed for frontline treatment of NPM1-mutated acute myeloid leukemia Expanded executive team and board of directors with hiring of COO and CFO and appointment of audit committee |
|
| November 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39592 Krono |
|
| November 18, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2020 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File |
|
| October 14, 2020 |
Exhibit 99.1 Kronos Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares San Mateo, Calif., and Cambridge, Mass., October 14, 2020 – Kronos Bio, Inc. (Nasdaq: KRON), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting |
|
| October 14, 2020 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KRONOS BIO, INC. Norbert Bischofberger, Ph.D., hereby certifies that: ONE: He is the duly elected President and Chief Executive Officer of Kronos Bio, Inc., a Delaware corporation. TWO: The original name of the corporation is Ponderosa Biosciences, Inc. and the original date of filing of said corporation’s original certificate of inc |
|
| October 14, 2020 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF KRONOS BIO, Inc. ARTICLE I OFFICES Section 1.Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2.Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by the corporation’s Board o |
|
| October 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2020 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39592 82-1895605 (State or other jurisdiction of incorporation) (Commission File |
|
| October 9, 2020 |
Exhibit 99.2 KRONOS BIO, INC. 2020 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: OCTOBER 1, 2020 APPROVED BY THE STOCKHOLDERS: OCTOBER 2, 2020 1.General. (a)Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) the Prior Plan’s Available Re |
|
| October 9, 2020 |
13,157,895 Shares Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-248925 13,157,895 Shares Common Stock This is the initial public offering of shares of common stock of Kronos Bio, Inc. We are offering 13,157,895 shares of our common stock. Prior to this offering, there has been no public market for our common stock. The initial public offering price is $19.00 per share of our common stock. Our common stock h |
|
| October 9, 2020 |
Exhibit 99.3 KRONOS BIO, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: OCTOBER 1, 2020 APPROVED BY THE STOCKHOLDERS: OCTOBER 2, 2020 IPO DATE: , 2020 1.GENERAL; PURPOSE. (a)The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan permits the C |
|
| October 9, 2020 |
As filed with the Securities and Exchange Commission on October 9, 2020 Registration No. |
|
| October 8, 2020 |
As filed with the Securities and Exchange Commission on October 8, 2020. Registration No. 333-248925 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 82-1895605 (State or other jurisdiction of incorporation |
|
| October 6, 2020 |
October 6, 2020 Via EDGAR Submission Securities and Exchange Commission Division of Corporation Finance 100 F Street N. |
|
| October 6, 2020 |
As filed with the Securities and Exchange Commission on October 6, 2020. Registration No. 333-248925 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 82-1895605 (State or other jurisdiction of incorporation |
|
| October 6, 2020 |
KRONOS BIO, INC. 1300 So. El Camino Real, Suite 300 San Mateo, California 94402 October 6, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Deanna Virginio Tim Buchmiller Sasha Parikh Julie Sherman Re: Kronos Bio, Inc. Registration Statement on Form S-1, as amended (File No. 333-248925) Request for Acceleration o |
|
| October 5, 2020 |
Exhibit 10.5 April 30, 2018 Norbert Bischofberger, Ph.D. Re: Employment Letter Dear Norbert: Kronos Bio, Inc. (“Kronos” or the “Company”) is pleased to offer you the position of President and Chief Executive Officer, on the following terms and conditions: 1.Title; Reporting; Duties. (a)You shall serve as the Company’s President and Chief Executive Officer and shall be appointed to, and made a memb |
|
| October 5, 2020 |
Exhibit 4.1 KB INCORPORATED UNDER THE CUSIP 50107A 10 4 LAWS OF THE STATE OF DELAWARE SEE REVERSE FOR CERTAIN DEFINITIONS AND LEGENDS This certifies that BY: REGISTERED: COUNTERSIGNED AND AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC (BROOKLYN, NY) TRANSFER AGENT is the record holder of FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.001 PAR VALUE PER SHARE, OF Kronos Bio, Inc. transferable |
|
| October 5, 2020 |
Charles J. Bair +1 858 550 6142 [email protected] October 5, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Deanna Virginio and Tim Buchmiller Re: Kronos Bio, Inc. Registration Statement on Form S-1 Filed September 18, 2020 File No. 333-248925 Ladies and Gentlemen: On behalf of Kronos Bio, Inc. (“Kronos” or the “Company”) |
|
| October 5, 2020 |
Exhibit 10.3 KRONOS BIO, INC. 2020 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: OCTOBER 1, 2020 APPROVED BY THE STOCKHOLDERS: OCTOBER 2, 2020 1.General. (a)Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) the Prior Plan’s Available Re |
|
| October 5, 2020 |
Form of Underwriting Agreement. Exhibit 1.1 Kronos Bio, Inc. Common Stock Underwriting Agreement [•], 2020 Goldman Sachs & Co. LLC Jefferies LLC Cowen and Company, LLC Piper Sandler & Co. As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto, c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282-2198 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Cowen |
|
| October 5, 2020 |
Third Amended and Restated Certificate of Incorporation, as amended, as currently in effect. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KRONOS BIO, INC. KRONOS BIO, INC. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: ONE: The name of the Corporation is Kronos Bio, Inc. TWO: The date of filing the original Certifica |
|
| October 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 82-1895605 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 1300 |
|
| October 5, 2020 |
As filed with the Securities and Exchange Commission on October 5, 2020. Registration No. 333-248925 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 82-1895605 (State or other jurisdiction of incorporation |
|
| October 5, 2020 |
Exhibit 10.1 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , 20, is made by and between KRONOS BIO, INC., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS A. The Company desires to attract and retain the services of highly qualified individuals as directors, officers, employees and agents. B. The Company’s Amended and Restated Bylaws (the “Bylaws”) |
|
| October 5, 2020 |
Non-Employee Director Compensation Policy. Exhibit 10.12 KRONOS BIO, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY ADOPTED: SEPTEMBER 30, 2020 Each member of the Board of Directors (the “Board”) of Kronos Bio, Inc. (the “Company”) who is a non-employee director of the Company (each such member, a “Non-Employee Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (the “Director Compensation P |
|
| October 5, 2020 |
Kronos Bio, Inc. 2020 Employee Stock Purchase Plan. Exhibit 10.4 KRONOS BIO, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: OCTOBER 1, 2020 APPROVED BY THE STOCKHOLDERS: OCTOBER 2, 2020 IPO DATE: , 2020 1.GENERAL; PURPOSE. (a)The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan permits the C |
|
| September 25, 2020 |
Charles J. Bair +1 858 550 6142 [email protected] BY EDGAR *FOIA Confidential Treatment Request* Confidential Treatment Requested by Kronos Bio, Inc. in connection with its Registration Statement on Form S-1 (File No. 333-248925) September 25, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Deanna Virginio Tim Buchmiller S |
|
| September 18, 2020 |
Exhibit 10.9 OFFICE LEASE BY AND BETWEEN DWF IV 1300 S EL CAMINO, LLC, A Delaware limited liability company, As Landlord And KRONOS BIO, INC., a Delaware corporation, as Tenant For Leased Premises at Suite 300, 1300 South El Camino Real, San Mateo, California 94402 TABLE OF CONTENTS ARTICLE 1 SALIENT LEASE TERMS 1 ARTICLE 2 ADDITIONAL DEFINITIONS 3 ARTICLE 3 PREMISES AND COMMON AREAS 8 ARTICLE 4 T |
|
| September 18, 2020 |
Bylaws, as currently in effect. Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF PONDEROSA BIOSCIENCES, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1.Registered Office. The registered office of the corporation in the State of Delaware shall be 251 Little Falls Drive, City of Wilmington, County of New Castle, 19808 or in such other location as the Board of Directors may from time to time determine or the business of the cor |
|
| September 18, 2020 |
Exhibit 10.2 KRONOS BIO, INC. 2017 EQUITY INCENTIVE PLAN SECTION 1. DEFINITIONS As used herein, the following terms shall have the meanings indicated below: (a)"Administrator" shall mean the Board of Directors of the Company, or one or more Committees appointed by the Board, as the case may be. (b)"Affiliate(s)" shall mean a Parent or Subsidiary of the Company. (c)"Award" shall mean any grant of a |
|
| September 18, 2020 |
Exhibit 2.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. CONFIDENTIAL EXECUTION VERSION ASSET PURCHASE AGREEMENT between KRONOS BIO, INC. and GILEAD SCIENCES, INC. Dated as of July 14, 2020 CONTENTS ARTICLE 1. DEFINITIONS 1 1.1 Defined Terms 1 1.2 Add |
|
| September 18, 2020 |
Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KRONOS BIO, INC. Norbert Bischofberger, Ph.D., hereby certifies that: ONE: He is the duly elected President and Chief Executive Officer of Kronos Bio, Inc., a Delaware corporation. TWO: The original name of the corporation is Ponderosa Biosciences, Inc. and the original date of filing of said corporation’s original certificate of inc |
|
| September 18, 2020 |
As filed with the Securities and Exchange Commission on September 18, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Kronos Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 82-1895605 (State or other jurisdiction of incorporation or organization) (Prim |
|
| September 18, 2020 |
Letter Agreement, by and between the registrant and Philip P. Gutry, dated September 19, 2018. Exhibit 10.7 September 19, 2018 Philip P. Gutry Re: Employment Letter Dear Mr. Gutry: Kronos Bio, Inc. (“Kronos” or the “Company”) is pleased to offer you the position of Chief Business Officer, on the following terms and conditions: 1.Title; Reporting; Duties. (a)As Chief Business Officer, you will perform such duties as are customarily provided by a Chief Business Officer of a similarly situated |
|
| September 18, 2020 |
Exhibit 10.10 Execution Version LEASE by and between BMR-ROGERS STREET LLC, a Delaware limited liability company and KRONOS BIO, INC. a Delaware corporation Table of Contents 1. Lease of Premises 1 2. Basic Lease Provisions 2 3. Term 4 4. Possession and Commencement Date. 4 5. Condition of Premises 6 6. Rentable Area 7 7. Rent 7 8. Rent Adjustments; Free Rent Period 8 9. Operating Expenses 8 10. T |
|
| September 18, 2020 |
Exhibit 10.5 April 30, 2018 Norbert Bischofberger, Ph.D. Re: Employment Letter Dear Norbert: Kronos Bio, Inc. (“Kronos” or the “Company”) is pleased to offer you the position of President and Chief Executive Officer, on the following terms and conditions: 1.Title; Reporting; Duties. (a)You shall serve as the Company’s President and Chief Executive Officer and shall be appointed to, and made a memb |
|
| September 18, 2020 |
Exhibit 10.6 Confidential September 4, 2019 Jorge F. DiMartino, MD, PhD Re: Employment Letter Dear Dr. DiMartino: Kronos Bio, Inc. (the "Company") is pleased to offer you the position of Chief Medical Officer, on the following terms and conditions: 1.Title; Reporting; Duties. (a)As Chief Medical Officer, you will perform such duties as are customarily provided by a Chief Medical Officer of a simil |
|
| September 18, 2020 |
Exhibit 10.11 LICENSE AGREEMENT This License Agreement (this “Agreement”) is entered into as of this 16th day of January, 2018 (the “Effective Date”), by and between Kronos Bio, Inc., a corporation existing under the laws of Delaware, having a place of business at 689 5th Avenue, 12th Floor, New York, NY 10022 (“Licensee”) and President and Fellows of Harvard College, an educational and charitable |
|
| September 18, 2020 |
Third Amended and Restated Certificate of Incorporation, as currently in effect. Exhibit 3.1 Delaware Page 1 The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE RESTATED CERTIFICATE OF “KRONOS BIO, INC.”, FILED IN THIS OFFICE ON THE FIRST DAY OF JULY, A.D. 2019, AT 9:45 O`CLOCK A.M. A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS. /s/ |
|
| September 18, 2020 |
Exhibit 4.2 Execution Version KRONOS BIO, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of July 1, 2019, by and among Kronos Bio, Inc., a Delaware corporation (the “Company”), the holders of the Company’s Series Seed Preferred Stock, par value $0.001 per share (the “Series Seed Preferred Stock”), listed on |
|
| September 18, 2020 |
September 18, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Deanna Virginio and Tim Buchmiller Re: Kronos Bio, Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted September 3, 2020 CIK No. 0001741830 Ladies and Gentlemen: On behalf of Kronos Bio, Inc. (“Kronos” or the “Company”), we are responding |
|
| September 18, 2020 |
Form of Amended and Restated Bylaws to become effective upon the closing of this offering. Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF KRONOS BIO, INC. ARTICLE I OFFICES Section 1.Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2.Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by the corporation’s Board o |
|
| September 18, 2020 |
Letter Agreement, by and between the registrant and Yasir Al-Wakeel, dated August 16, 2020. Exhibit 10.8 August 14, 2020 Dr. Yasir Al-Wakeel Re: Employment Letter Dear Dr. Al-Wakeel: Kronos Bio, Inc. (the “Company”) is pleased to offer you the position of Chief Financial Officer and Head of Corporate Development and Strategy of the Company, on the following terms and conditions: 1.Title; Reporting; Duties. (a)As Chief Financial Officer and Head of Corporate Development and Strategy, you |
|
| September 3, 2020 |
ASSET PURCHASE AGREEMENT KRONOS BIO, INC. GILEAD SCIENCES, INC. Dated as of July 14, 2020 Exhibit 2.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. CONFIDENTIAL EXECUTION VERSION ASSET PURCHASE AGREEMENT between KRONOS BIO, INC. and GILEAD SCIENCES, INC. Dated as of July 14, 2020 CONTENTS ARTICLE 1. DEFINITIONS 1 1.1 Defined Terms 1 1.2 Add |
|
| September 3, 2020 |
KRONOS BIO, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT Exhibit 4.2 Execution Version KRONOS BIO, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of July 1, 2019, by and among Kronos Bio, Inc., a Delaware corporation (the “Company”), the holders of the Company’s Series Seed Preferred Stock, par value $0.001 per share (the “Series Seed Preferred Stock”), listed on |
|
| September 3, 2020 |
Charles J. Bair +1 858 550 6142 [email protected] September 3, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Deanna Virginio and Tim Buchmiller Re: Kronos Bio, Inc. Draft Registration Statement on Form S-1 Submitted July 31, 2020 CIK No. 0001741830 Ladies and Gentlemen: On behalf of Kronos Bio, Inc. (“Kronos” or the “Com |
|
| September 3, 2020 |
Exhibit 10.8 August 14, 2020 Dr. Yasir Al-Wakeel Re: Employment Letter Dear Dr. Al-Wakeel: Kronos Bio, Inc. (the “Company”) is pleased to offer you the position of Chief Financial Officer and Head of Corporate Development and Strategy of the Company, on the following terms and conditions: 1.Title; Reporting; Duties. (a)As Chief Financial Officer and Head of Corporate Development and Strategy, you |
|
| September 3, 2020 |
As co nfidentially submitted to the Securities and Exchange Commission on September 3 , 2020. |
|
| July 31, 2020 |
Exhibit 10.7 September 19, 2018 Philip P. Gutry 2 Grimes Road Old Greenwich, CT 06870 Re: Employment Letter Dear Mr. Gutry: Kronos Bio, Inc. (“Kronos” or the “Company”) is pleased to offer you the position of Chief Business Officer, on the following terms and conditions: 1.Title; Reporting; Duties. (a)As Chief Business Officer, you will perform such duties as are customarily provided by a Chief Bu |
|
| July 31, 2020 |
As confidentially submitted to the Securities and Exchange Commission on July 31, 2020. |
